Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...

Monoclonal antibodies target specific disease molecules. They can help treat cancer, autoimmune disorders, and infectious diseases. Discover what you should know about this therapy. Monoclonal ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Monoclonal antibodies (mAbs) make up one of the most important classes of advanced biotherapies. To find out about the current challenges and advances in the production of mAbs, GEN talked with Lukas ...

The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of age ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and rare ...

A team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is needed, but the ...

Engage: A Survivorship Program to Improve Childhood Cancer Survivors' Self-Efficacy and Quality of Life The development of subcutaneous (SC) formulations for monoclonal antibodies (mAbs), as an ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 human challenge trial will measure time to recovery from dengue and determine effective doses of the ...

The FDA on Friday revoked the emergency use authorizations (EUAs) of four monoclonal antibodies for COVID-19. The four drugs -- bebtelovimab, sotrovimab, casirivimab ...

Important adverse events included infusion-related and hypersensitivity reactions in 25 of 306 immunocompromised participants (8.2%) who received pemivibart and anaphylaxis in 4 of 623 participants (0 ...